Shattuck Labs, Inc. (STTK): R&D Expense
$35.27M
Year ended 2025-12-31
$39.32M
Trailing 12 months to 2026-06-30
-24.8%
3-year compound annual growth
-1.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $35.27M | -47.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $67.21M | -9.6% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $74.31M | -10.4% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $82.90M | +46.6% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $56.56M | +50.9% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $37.48M | +28.3% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $29.22M | n/a | 2021-03-16, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
Compare STTK, SXTP, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗